In vitro, strontium ranelate increases collagen and noncollagen protein synthesis by mature osteoblast-enriched cells. Its effects on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated osteoclast, preincubation of bone slices with strontium ranelate-induced dose-dependent inhibition of the bone-resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. Its effect in postmenopausal women with established osteoporosis was assessed during an international, prospective, double-blind, randomized, placebo-controlled phase 3 program comparing strontium ranelate 2 g daily with placebo. The 3-year analysis of the phase 3 study, Spinal Osteoporosis Therapeutic Intervention, evaluating the effect of strontium ranelate 2 g/day on vertebral fracture rates, revealed a significant 41% reduction in the relative risk of patients experiencing new vertebral fracture with strontium ranelate over 3 years. A second phase 3 study showed a significant reduction in the relative risk of experiencing a nonvertebral fracture in the group treated with strontium ranelate over 3 years. These results show that strontium ranelate is a new, effective, and safe treatment for vertebral and hip osteoporosis, with a unique mode of action, increasing bone formation and decreasing bone resorption leading to a rebalance of bone turnover in favor of bone formation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Canalis E, Hott M, Deloffre P, et al.: The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996, 18:517–523.
Marie PJ, Ammann P, Boivin G, Rey C: Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001, 69:121–129.
Izumisawa T, Morohashi T, Amano H, Yamada S: The effect of stable strontium on calcium metabolism: II. Effect of 1-hydroxyvitamin D3 in strontium-fed rats and inhibitory effect of strontium on bone resorption in vitro. J Bone Miner Metab 1994, 12:43–49.
Takahashi N, Sasaki T, Tsouderos Y, Suda T: S12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003, 18:1082–1087.
Baron R, Tsouderos Y: In vitro effects of S12911-2 on osteo-clast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002, 450:11–17.
Buehler J, Chappuis P, Saffar JL, et al.: Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001, 29:176–179.
Boivin G, Deloffre P, Perrat B, et al.: Strontium distribution and interactions with bone mineral density in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res 1996, 11:1302–1311.
Morohashi T, Sano T, Harai K, Yamada S: Effects of strontium on calcium metabolism in rats II. Strontium prevents the increased rate of bone turnover in ovariectomized rats. Jpn J Pharmacol 1995, 68:153–159.
Marie PJ, Hott M, Modrowski D, et al.: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8:607–615.
Hott M, Deloffre P, Tsouderos Y, Marie PJ: S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003, 33:115–123.
Meunier PJ, Slosman D, Delmas P, et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002, 87:2060–2066. The first trial showing an effect on strontium ranelate on BMD and biochemical markers of bone turnover in postmenopausal women.
Boivin G, Foos E, Tupinon-Mathieu I, Meunier PJ: Strontium deposition in bone is dose dependent and does not alter the degree of mineralization of bone in osteoporotic patients treated with strontium ranelate. J Bone Miner Res 2000, 15(Suppl 1):305.
Reginster JY, Diez-Perez A, Ortolani S, et al.: Calcium-vitamin D supplementation in clinical trials of osteoporosis should be titrated on the basis of pre-study assessments. Osteoporos Int 2002, 13(Suppl 1):S24.
Reginster JY, Spector T, Badurski J, et al.: A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate Phase III program. Osteoporos Int 2002, 13(Suppl 1):S30.
Genant HK, Wu CY, Van Kuijk C, Newit MC: Vertebral semi quantitative assessment using a semi-quantitative technique. J Bone Miner Res 1993, 8:1137–1148.
Meunier PJ, Roux Ortolani S, et al.: Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 2002, 13(Suppl 1):O45.
Meunier PJ, Roux Seeman E, et al.: The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459–468. A prospective double-blind randomized study demonstrating the antifracture efficacy of strontium ranelate, in spinal osteoporosis in postmenopausal women.
Rizzoli R, Reginster JY, Diaz-Curiel M, et al.: Patients at high risk of hip fracture benefit from treatment with strontium ranelate. Osteoporos Int 2004, 15(Suppl 1):OC39.
Reginster JY, Rizzoli R, Balogh A, et al.: Strontium ranelate reduces the risk of vertebral fractures in osteoporotic post menopausal women without prevalent vertebral fracture. Calcif Tissue Int 2004, 74(Suppl 1):P151.
About this article
Cite this article
Reginster, JY., Sarlet, N., Lejeune, E. et al. Strontium ranelate: A new treatment for postmenopausal osteoporosis with a dual mode of action. Curr Osteoporos Rep 3, 30–34 (2005). https://doi.org/10.1007/s11914-005-0025-7
- Vertebral Fracture
- Bone Mineral Content
- Strontium Ranelate
- Increase Bone Formation